Comparison between radiation to only involved node and involved side of node as well as comparison between when patient will inhale deeply and then hold his /her breath and without imposing any restriction in respiratio
Phase 2
- Conditions
- Health Condition 1: null- Age equal or greater than 18 yearsPerformance score less than 2Patients able to tolerate breath-hold of more or equal than 15 seconds as measured by a stopwatch in the clinic
- Registration Number
- CTRI/2018/01/011513
- Lead Sponsor
- Rimpa Basu Achari
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Previously untreated patients diagnosed with Hodgkinâ??s lymphoma bulky mediastinal involvement where mediastinal RT is expected to be a part of the combined modality treatment
2. Age equal or greater than 18 years
3. Performance score less than 2
4. Patients able to tolerate breath-hold of more or equal than 15 seconds as measured by a stopwatch in the clinic
5. Signed informed consent
Exclusion Criteria
1.Inability to hold breath in inspiration for at least 15 seconds measured by a stop watch after adequate chest physiotherapy.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Compare International Lymphoma Radiation Oncology Group (ILROG) Involved Site Radiotherapy (ISRT) versus the European Organisation of Research and Treatment of Cancer (EORTC) Involved Node Radiotherapy (INRT) volumes for mediastinal radiation in Hodgkinâ??s lymphomaTimepoint: 3 years
- Secondary Outcome Measures
Name Time Method 1. Quantify the dosimetric differences between the deep inspiration breath hold (DIBH) technique and the free breathing (FB) technique treatment plans to detect dose differences for organs at risk organs at risk from radiation, if any. <br/ ><br>2. Paraffin block [when available] banking for future radiobiology sub-studies in context off lymphoma outcomes and late normal tissue effects. When designed, this will be re-submitted as an independent protocol in futureTimepoint: 3 years